You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

MELOXICAM - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for meloxicam and what is the scope of patent protection?

Meloxicam is the generic ingredient in six branded drugs marketed by Lupin Ltd, Novitium Pharma, Iceutica Operations, Baudax, Avondale Pharms, Tersera, Aiping Pharm Inc, Anda Repository, Ascent Pharms Inc, Aurobindo Pharma, Chartwell Rx, Cipla, Corepharma, Cr Double Crane, Dr Reddys Labs Inc, Esjay Pharma, Glenmark Pharms Ltd, Impax Labs Inc, Lupin Pharms, Mylan, Natco Pharma, Puracap Pharm, Roxane, Sun Pharm Inds Inc, Taro, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, Boehringer Ingelheim, and Axsome, and is included in thirty-one NDAs. There are nine patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Meloxicam has sixty-four patent family members in twenty-two countries.

There are twenty-two drug master file entries for meloxicam. Forty-two suppliers are listed for this compound.

Drug Prices for MELOXICAM

See drug prices for MELOXICAM

Drug Sales Revenue Trends for MELOXICAM

See drug sales revenues for MELOXICAM

Recent Clinical Trials for MELOXICAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MiamiPhase 4
TriHealth Inc.Phase 3
Baptist Health South FloridaPhase 4

See all MELOXICAM clinical trials

Pharmacology for MELOXICAM
Paragraph IV (Patent) Challenges for MELOXICAM
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIVLODEX Capsules meloxicam 5 mg and 10 mg 207233 1 2017-01-09
MELOXICAM Oral Suspension meloxicam 7.5 mg/5 mL 021530 1 2009-12-17

US Patents and Regulatory Information for MELOXICAM

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Boehringer Ingelheim MOBIC meloxicam TABLET;ORAL 020938-001 Apr 13, 2000 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Boehringer Ingelheim MOBIC meloxicam TABLET;ORAL 020938-002 Aug 23, 2000 DISCN Yes No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Natco Pharma MELOXICAM meloxicam TABLET;ORAL 077923-002 Jul 19, 2006 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Lupin Pharms MELOXICAM meloxicam TABLET;ORAL 077944-001 Jul 19, 2006 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Axsome SYMBRAVO meloxicam; rizatriptan benzoate TABLET;ORAL 215431-001 Jan 30, 2025 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 5 of 5 entries

Expired US Patents for MELOXICAM

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 ⤷  Try for Free ⤷  Try for Free
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 ⤷  Try for Free ⤷  Try for Free
Baudax ANJESO meloxicam SOLUTION;INTRAVENOUS 210583-001 Feb 20, 2020 ⤷  Try for Free ⤷  Try for Free
Avondale Pharms MELOXICAM meloxicam SUSPENSION;ORAL 021530-001 Jun 1, 2004 ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 4 of 4 entries

EU/EMA Drug Approvals for MELOXICAM

CompanyDrugnameInnProduct Number / IndicationStatusGenericBiosimilarOrphanMarketing AuthorisationMarketing Refusal
Boehringer Ingelheim Vetmedica GmbH Metacam meloxicam EMEA/V/C/000033
Cats:Alleviation of mild to moderate post-operative pain and inflammation following surgical procedures, e.g. orthopaedic and soft tissue surgery.Alleviation of pain and inflammation in acute and chronic musculo-skeletal disorders.Reduction of post-operative pain after ovariohysterectomy and minor soft tissue surgery.Cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of post-operative pain following dehorning in calves.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.Dogs:Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders.Reduction of post-operative pain and inflammation following orthopaedic and soft tissue surgery.Horses:For use in the alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.For the relief of pain associated with equine colic.Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders.Pigs: For use in non-infectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of post-operative pain associated with minor soft tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Guinea pigs:Alleviation of mild to moderate post-operative pain associated with soft tissues surgery such as male castration.
Authorised no no no 1998-01-07
Boehringer Ingelheim Vetmedica GmbH Novem meloxicam EMEA/V/C/000086
Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.
Authorised no no no 2004-03-02
Norbrook Laboratories (Ireland) Limited Loxicom meloxicam EMEA/V/C/000141
DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.
Authorised yes no no 2009-02-10
Le Vet Beheer B.V Meloxidolor meloxicam EMEA/V/C/002590
DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.
Authorised yes no no 2013-04-22
Le Vet Beheer B.V.  Novaquin meloxicam EMEA/V/C/003866
Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.
Authorised no no no 2015-09-08
>Company>Drugname>Inn>Product Number / Indication>Status>Generic>Biosimilar>Orphan>Marketing Authorisation>Marketing Refusal
Showing 1 to 5 of 5 entries

International Patents for MELOXICAM

CountryPatent NumberTitleEstimated Expiration
European Patent Office 3151835 NOUVELLE FORMULATION DE MÉLOXICAM (A NOVEL FORMULATION OF MELOXICAM) ⤷  Try for Free
European Patent Office 3870163 ⤷  Try for Free
Japan 2021527697 ⤷  Try for Free
Japan 2022505572 ⤷  Try for Free
Japan 2016053028 ⤷  Try for Free
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 5 of 5 entries

Market Dynamics and Financial Trajectory for Meloxicam

Introduction

Meloxicam, a nonsteroidal anti-inflammatory drug (NSAID) and a selective COX-2 inhibitor, is widely used for the treatment of various forms of arthritis, including osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis. The market for meloxicam is experiencing significant growth, driven by several key factors.

Market Size and Growth Projections

The global meloxicam market is anticipated to expand substantially over the coming years. By 2036, the market size is expected to reach USD 47 billion, growing at a Compound Annual Growth Rate (CAGR) of around 5% from 2024 to 2036. In 2023, the market size was over USD 7 billion[1][4].

Growth Drivers

Increasing Prevalence of Arthritis

The rising incidence of osteoarthritis, rheumatoid arthritis, and other chronic pain conditions, particularly among the aging population, is a major driver of the meloxicam market. According to the World Health Organization, 60% of those with osteoarthritis are female, and 73% are older than 55 years. The knee is the most frequently affected joint, with an estimated 365 million cases worldwide[1].

Awareness and Availability of Pain Relief Medication

Increased awareness about the availability of pain relief medications has also contributed to the market growth. The population is becoming more informed about treatment options, which is boosting the demand for meloxicam[1].

Combination Drugs

The market for combination drugs, which include meloxicam, is set to grow significantly. For example, ZYNRELEF, a combination of bupivacaine and meloxicam, has seen increased sales due to its effectiveness in treating multiple conditions simultaneously[2].

Market Segmentation

By Disease

The osteoarthritis segment is expected to account for the largest revenue share, approximately 40% by the end of 2036. This is due to the high prevalence of osteoarthritis and the use of meloxicam as a preferred treatment option[1].

By Drug Type

The market is segmented into generic and branded drugs. The generic segment is expected to grow significantly due to its cost-effectiveness and wider availability[4].

By Population Type

Meloxicam is used across various population types, including adults and children. The adult segment dominates the market due to the higher incidence of arthritis among this demographic[4].

By Dosage and Dose Strength

Meloxicam is available in various dosages, including oral, parenteral, and transdermal forms. The oral dosage form is the most common, with dose strengths of 7.5mg and 15mg being widely prescribed[4].

Regional Market Analysis

North America

The North American region is anticipated to account for the largest revenue share, approximately 33% by the end of the forecast period. This growth is driven by the increasing number of arthritis patients and the robust healthcare infrastructure in the region. According to the National Health Interview Survey, an estimated 58.5 million US adults have been diagnosed with some form of arthritis[1].

Asia Pacific

The Asia Pacific region is expected to see significant growth due to the increasing aging population and the rising incidence of osteoarthritis and rheumatoid arthritis. Favorable reimbursement policies for generic drugs in this region are also driving market growth[1].

Financial Performance and Trends

Revenue Growth

Companies like Heron Therapeutics, which markets ZYNRELEF, have seen positive revenue growth. In 2023, ZYNRELEF achieved a quarterly record of $5.6 million in net product sales, with full-year sales reaching $17.7 million. This indicates a growing demand for meloxicam-based products[2].

Cost Efficiency

Studies have shown that meloxicam is a cost-efficient treatment option compared to other NSAIDs. An economic evaluation revealed that meloxicam had the lowest cost per patient, resulting in significant cost savings for healthcare systems[5].

Challenges and Limitations

Side Effects

Despite its benefits, meloxicam is associated with side effects such as ulcers, dizziness, and other gastrointestinal issues. These side effects can hamper market growth and necessitate careful patient monitoring[4].

Market Competition

The meloxicam market faces competition from other pain management medications, including opioids and other NSAIDs. However, the preference for NSAIDs over opioids due to their lower risk of addiction is a positive trend for meloxicam[4].

Key Takeaways

  • The global meloxicam market is projected to reach USD 47 billion by 2036, driven by the increasing prevalence of arthritis and chronic pain conditions.
  • The North American and Asia Pacific regions are expected to be significant contributors to market growth.
  • Combination drugs like ZYNRELEF are gaining traction due to their multi-condition treatment capabilities.
  • Meloxicam is a cost-efficient treatment option compared to other NSAIDs.
  • Side effects and market competition are key challenges that need to be addressed.

FAQs

What is the projected market size of meloxicam by 2036?

The global meloxicam market is anticipated to reach USD 47 billion by the end of 2036[1].

Which region is expected to account for the largest revenue share in the meloxicam market?

The North American region is expected to account for the largest revenue share, approximately 33% by the end of the forecast period[1].

What are the primary growth drivers for the meloxicam market?

The primary growth drivers include the increasing prevalence of osteoarthritis, rheumatoid arthritis, and other chronic pain conditions, as well as increased awareness about pain relief medications[1].

What are the common side effects associated with meloxicam?

Common side effects include ulcers, dizziness, and other gastrointestinal issues[4].

How does meloxicam compare to other NSAIDs in terms of cost efficiency?

Meloxicam is predicted to be the lowest cost drug therapy compared to nonselective NSAIDs like diclofenac and piroxicam, resulting in significant cost savings for healthcare systems[5].

Sources:

  1. Research Nester, Meloxicam Market Size - Global Forecast Report 2036, November 2, 2023.
  2. Heron Therapeutics, Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates, March 12, 2024.
  3. Market Research Intellect, Meloxicam Drug Sales: Insights into Growth Trends and Market Evolution, October 1, 2024.
  4. Data Bridge Market Research, Global Meloxicam Market - Industry Trends and Forecast to 2028.
  5. PubMed, An economic evaluation of meloxicam versus diclofenac and piroxicam.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.